Curcumol improves cisplatin sensitivity of human gastric cancer cells through inhibiting PI3K/AKT pathway

• DOI: 10.1002/ddr.21719
• Publication Date: 2020-07-27T05:42:20Z
• Authors: Xiaofei Huang; Jun Qian; Lingchang Li; Xiaozhen Zhang; Guoli Wei; Jian Lv; Fengxia Qin; Jialin Yu; Ya Xiao; Zhen Gong; Jiege Huo
• Keywords: MTT assay; Viability assay

Abstract Background Curcumol was presented to unleash antitumor effects in a variety of cancers, including gastric cancer. However, the relevance between curcumol and cisplatin resistance cancer still remains unclear. Therefore, current research performed survey role sensitivity Methods First, BGC‐823 BGC‐823/DDP cells were incubated with for 48 hr 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,5‐diphenyl‐2‐H‐tetrazolium bromide (MTT) analysis applied determine inhibition rate cell proliferation half‐maximal inhibitory concentration (IC 50 ) cisplatin. In addition, treated followed detection viability apoptosis using MTT flow cytometry assay, respectively. Moreover, test on cells. Lastly, Western blot assay qRT‐PCR utilized check functions PI3K/AKT pathway‐related markers. Results We found that exhibited stronger compared Furthermore, evidently reduced facilitated results from demonstrated notably promoted suppression effect decreased IC It also suppressed pathway dose‐dependently Conclusion The findings could promote cisplatin‐based chemotherapies via inhibiting phosphatidylinositol 3‐kinase (PI3K)/Protein Kinase B (AKT) pathway.